JP2020502103A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502103A5
JP2020502103A5 JP2019531417A JP2019531417A JP2020502103A5 JP 2020502103 A5 JP2020502103 A5 JP 2020502103A5 JP 2019531417 A JP2019531417 A JP 2019531417A JP 2019531417 A JP2019531417 A JP 2019531417A JP 2020502103 A5 JP2020502103 A5 JP 2020502103A5
Authority
JP
Japan
Prior art keywords
pyrimidine
triazine
pyrrolo
trifluoromethyl
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019531417A
Other languages
English (en)
Japanese (ja)
Other versions
JP7150721B2 (ja
JP2020502103A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/066317 external-priority patent/WO2018112149A1/en
Publication of JP2020502103A publication Critical patent/JP2020502103A/ja
Publication of JP2020502103A5 publication Critical patent/JP2020502103A5/ja
Application granted granted Critical
Publication of JP7150721B2 publication Critical patent/JP7150721B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019531417A 2016-12-16 2017-12-14 Cftr増強物質としての二環式ヘテロアリール誘導体 Active JP7150721B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662435253P 2016-12-16 2016-12-16
US62/435,253 2016-12-16
PCT/US2017/066317 WO2018112149A1 (en) 2016-12-16 2017-12-14 Bycyclic heteroaryl derivatives as cftr potentiators

Publications (3)

Publication Number Publication Date
JP2020502103A JP2020502103A (ja) 2020-01-23
JP2020502103A5 true JP2020502103A5 (enExample) 2022-05-24
JP7150721B2 JP7150721B2 (ja) 2022-10-11

Family

ID=62557188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531417A Active JP7150721B2 (ja) 2016-12-16 2017-12-14 Cftr増強物質としての二環式ヘテロアリール誘導体

Country Status (10)

Country Link
US (4) US10131670B2 (enExample)
EP (1) EP3554506B1 (enExample)
JP (1) JP7150721B2 (enExample)
CN (1) CN110300589B (enExample)
AU (2) AU2017378324B2 (enExample)
CA (1) CA3046968A1 (enExample)
MX (1) MX391651B (enExample)
RU (1) RU2753056C2 (enExample)
SG (2) SG10201911221RA (enExample)
WO (1) WO2018112149A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60906B1 (sr) 2014-10-06 2020-11-30 Vertex Pharma Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu
EA201890913A1 (ru) 2015-11-25 2018-11-30 Джилид Аполло, Ллс Пиразоловые соединения в качестве ингибиторов акк и их применение
EA201890949A1 (ru) 2015-11-25 2018-12-28 Джилид Аполло, Ллс СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
AU2016359626A1 (en) 2015-11-25 2018-05-17 Gilead Apollo, Llc Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno(2,3-d)pyrimidine
KR20180082557A (ko) 2015-11-25 2018-07-18 길리어드 아폴로, 엘엘씨 트리아졸 acc 억제제 및 그의 용도
LT3519401T (lt) 2016-09-30 2021-11-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
MX2021012639A (es) 2016-11-18 2022-10-03 Cystic Fibrosis Found Pirrolopirimidinas como potenciadores de cftr.
PT3551622T (pt) 2016-12-09 2020-11-12 Vertex Pharma Modulador do regulador da condutância transmembrana da fibrose quística, composições farmacêuticas, métodos de tratamento e processo de fabrico do modulador
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated METHODS OF TREATING CYSTIC FIBROSIS
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
CA3085006A1 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
CA3088577A1 (en) 2018-02-15 2019-08-22 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
EP3980121A1 (en) * 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
CN114007616A (zh) 2019-07-15 2022-02-01 诺华股份有限公司 (s)-3-氨基-6-甲氧基-n-(3,3,3-三氟-2-羟基-2-甲基丙基)-5-(三氟甲基)吡啶甲酰胺的配制品
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
US11873300B2 (en) 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
JP7784041B2 (ja) * 2020-04-07 2025-12-11 アイテオ ベルギウム エスエー がんの治療のためのent阻害剤としての大環状ジアミン誘導体、及びそれとアデノシン受容体拮抗薬との組合せ
WO2022036060A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
IL300405A (en) 2020-08-20 2023-04-01 Univ Leland Stanford Junior Methods for treating respiratory diseases characterized by excessive secretion of mucus
US12612416B2 (en) 2020-10-07 2026-04-28 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
IL303519A (en) 2020-12-10 2023-08-01 Vertex Pharma Cystic fibrosis treatment methods
CN112876524B (zh) * 2021-01-26 2022-10-28 上海法默生物科技有限公司 一种瑞德西韦中间体的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
TW200801008A (en) * 2005-12-29 2008-01-01 Abbott Lab Protein kinase inhibitors
EA200870409A1 (ru) * 2006-04-04 2009-04-28 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Антагонисты киназы pi3
CN101917999A (zh) * 2007-11-07 2010-12-15 弗尔德里克斯制药股份有限公司 蛋白质运输的调节
KR101793304B1 (ko) * 2010-02-05 2017-11-02 아드베리오 파마 게엠베하 낭성 섬유증의 치료를 위한, 단독으로의 및 PDE5 억제제와 조합된 sGC 자극제 또는 sGC 활성화제
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
CA2915418C (en) * 2013-07-02 2022-05-03 Rhizen Pharmaceuticals Sa Novel selective pi3k delta and/or gamma protein kinase inhibitors
MX2021012639A (es) 2016-11-18 2022-10-03 Cystic Fibrosis Found Pirrolopirimidinas como potenciadores de cftr.

Similar Documents

Publication Publication Date Title
RU2019120990A (ru) Бициклические гетероарильные производные в качестве стимуляторов cftr
RU2021129721A (ru) Пирролопиримидины в качестве потенциаторов мвтр
JP2024050527A5 (enExample)
JP2022505835A5 (enExample)
JP6294277B2 (ja) Hec1活性の調節因子およびそのための方法
JP2014513110A5 (enExample)
JP2012532112A5 (enExample)
JP2019510787A5 (enExample)
JP2014511891A5 (enExample)
JP2019529484A5 (enExample)
JP2017528498A5 (enExample)
JP2014037426A5 (enExample)
JP2014526501A5 (enExample)
JP2013537203A5 (enExample)
JP2011509309A5 (enExample)
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
JP2009516685A5 (enExample)
JP2016520131A5 (enExample)
JP2006524660A5 (enExample)
RU2016134751A (ru) Соединения
JP2021502387A5 (enExample)
JP2014506582A5 (enExample)
IL269710B2 (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in cancer therapy
JP2015536997A5 (enExample)
CA2628844A1 (en) Pyrazole derivatives and their medical use